Selbsthilfe bei Erkrankung der Prostata

Josef Dietz

Referenzen: Selektive Literaturrecherche zur diagnostischen und prognostischen Relevanz der DNA-Zytometrie beim Prostatakarzinom

  1. Adolfsson, J.; Rönström, L.; Hedlund, P.-O.; Löwhagen, T.; Carstensen, J.; Tribukait, B.: The prognostic value of modal deoxyribonucleic acid in low grade, low stage untreated prostate cancer, 1990, Journal of Urology, 144, 1404-1407.
  2. Ahlgren, G.; Lindholm, K.; Falkmer, U.; Abrahamsson, P.-A.: A DNA cytometric proliferation index improves the value of The DNA ploidy pattern as a prognosticating tool in patients with carcinoma oft the prostate, 1997, Urology, 50(3), 379-384.
  3. Allan, R.W., Sanderson H., Epstein, J.I.: Correlation of minute (0.5mm or less) focus of prostate adenocarcinoma on needle biopsy with radical prostatectomy specimen: role of prostate specific antigen density. 2003, Journal of Urology, 170 (2), 370-372.
  4. Allsbrook Jr., W.C.; Mangold, K.A.; Johnson, M.H. et al: Interobserver reproducibility of Gleason grading of prostatic carcinoma: general pathologist, 2001, Human Pathology, 32, 81-88.
  5. Allsbrook Jr., W.C.; Mangold, K.A.; Johnson, M.H. et al: Interobserver reproducibility of Gleason grading of prostatic carcinoma: urologic pathologists, 2001, Human Pathology, 32, 74-80.
  6. Amling, C.L.; Lerner, S.E.; Martin, S.K.; Slezak, J.M.; Blute, M.L.; Zincke, H.: Deoxyribonucleic acid ploidy and serum prostate specific antigen predict outcome following salvage prostatectomy for radiation refractory prostate cancer, 1999, Journal of Urology, 161, 857-863.
  7. Augustin, H., Hammerer, P.G., Graefen, M., Erbersdobler, A., Blonski, J., Palisaar, J., Daghofer, F, Huland, H.: Insignificant prostate cancer in radiacl prostatectomy specimen: time trends and preoperative prediction, European Urology, 43 (5), 455-460.
  8. Badalament, R.A.; O`Toole, R.V.; Young, D.C.; Drago, J.R.: DNA ploidy and prostate-specific antigen as prognostic factors in clinically resectable prostate cancer, 1991, Cancer, 67, 3014-3023.
  9. Bantis, A.; Gonidi, M.; Athanassiades, P.; Tsolos, C.; Liossi, A.; Aggelonidou, E.; Athanassiadou, A.M.; Petrakakou, E.; Athanassiadou, P.: Prognostic value of DNA analysis of prostate Aadenocarcinoma: Correlation to clinicopathologic predictors, 2005, Journal of Experimental & Clinical Cancer Research, 24, 273-278.
  10. Blute, M.L.; Nativ, O.; Zincke, H.; Farrow, G.M.; Therneau, T.; Lieber, M.M.: Pattern of failure after radical retropubic prostatectomy for clinically and pathologically localized adenocarcinoma of the prostate: influence of tumor deoxyribonucleic acid ploidy, 1989, Journal of Urology, 142, 1262-1265.
  11. Boccon-Gibod, L.M., Dumonceau, O., Toublanc, M., Ravery, V., Boccon-Gibod, L.A.: Micro-focal prostate cancer: a comparison of biopsy and radical prostatectomy specimen feature,. 2005, European Urology 48 (6), 895-899.
  12. Böcking, A.; Chatelain, R.; Orthen, U.; Gien, G.; v. Kalckreuth, G.; Jocham, D.; Wohltmann, D.: DNA-grading of prostatic carcinoma: Prognostic validity and reproducibility, 1988, Anticancer Research, 8, 129-135.
  13. Böcking, A.; Chatelain, R.; Homge, M.; Daniel, R.; Gillissen, A.; Wohltmann, D.: Representativity and reproducibility of DNA malignancy grading in different carcinomas, 1989, Analytical and Quantitative Cytology and Histology, 11(2), 81-86.
  14. Böcking, A.; Giroud, F.; Reith, A.: Consensus report of the ESACP task force on standardization of diagnostic DNA image cytometry, 1995, Analytical Cellular Pathology, 8, 67-74.
  15. Borre, M.; Høyer, M.; Nerstrøm, B.; Overgaard1, J.: DNA Ploidy and Survival of Patients With Clinically Localized Prostate Cancer Treated Without Intent to Cure, 1998, The Prostate 36:244–249
  16. Bostwick, D.G.; Grignon, D.J.; Hammond, M.E.; Amin, M.B.; Cohen, M.;Crawford, D.; Gospadarowicz, M.; Kaplan, R.S.; Miller, D.S.; Montironi, R.; Pajak, T.F.; Pollack, A.; Srigley, J.R.; Yarbro, J.W.: Prognostic factors in prostate cancer - College of American Pathologists Consensus Statement 1999, 2000, Archives of Pathology and Laboratory Medicine, 124, 995-1000.
  17. Brinker, D.A.; Ross, J.S.; Tran, T.A.; Jones, D.M.; Epstein, J.I.: Can ploidy of prostate carcinoma diagnosed on needle biopsy predict radical prostatectomy stage and grade? 1999, Journal of Urology, 162, 2036-2039.
  18. Burchardt, M., Engers, R., Müller, M., Burchardt, T., Willers, R., Epstein, J. I., Ackermann, R., Gabbert, H. E., de la Taille, J. I., Rubin, M. A.: Interobserver reproducibility of Gleason grading: evaluation using prostate cancer tissue microarrays. Journal of Cancer Research and Clinical oncoloy, 2008, 134, 1071 – 1078.
  19. Carlson, G.D.; Calvanese, C.B.; Kahane, H.; Epstein, J.I.: Accuracy of biopsy Gleason scores from a large unropathology laboratory: use of a diagnostic protocol to minimize observer variability, 1998, Urology, 51, 525-529.
  20. Carmichael, M.J.; Veltri, R.W.; Partin, A.W.; Miller, M.C.; Walsh, P.C.; Epstein, J.I.: Deoxyribonucleic acid ploidy analysis as a predictor of recurrence following radical prostatectomy for stage T2 disease, 1995, Journal of Urology, 153, 1015-1019.
  21. Carter, H.B., Epstein, J.I., Chan, D.W., Forzard, J.L., Pearson, J.D: Recommended prostate-specific antigen testing intervals for the detection of curable prostate cancer 1997, Journal of the American Medical Association77 (18), 1456-1460.
  22. Centeno, B.A.; Zietman, A.L.; Shipley, W.U.; Sobczak, M.L.; Shipley, J.W.; Preffer, F.I.; Boyle, B.J.; Colvin, R.B.: Flow cytometric analysis of DNA ploidy, percent S-phase fraction, and total proliferative fraction as prognostic indicators of local control and survival following radiation therapy for prostate carcinoma, 1994, International Journal of Radiation Oncology Biology Physics, 2, 309-315.
  23. Chan, T.Y., Chan, D.Y, Stutzman, K.L., Epstein, J.I: Does increased needle biopsy sampling of the prostate detect a higher number of potentially insignificant tumors? 2001, Journal of Urology, 166 (6), 2181-2184.
  24. Cintra, M.L.; Billis, A.: Histologic grading of prostatic adenocarcinoma: intraobserver reproducibility of the Mostofi, Gleason and Böcking grading systems, 1991, International Urology and Nephrology, 23(5), 449-454.
  25. Cupp, M.R., Bostwick, D.G., Myers, R.P., Oesterling, J.E.: The volume of prostate cancer in the biopsy specimen cannot reliably predict the quantity of cancer in the radical prostatectomy specimen on an individual basis, 1995, Journal of Urology, 153 (5), 1543-1548.
  26. De la Taille, A.; Viellefond, A.; Berger, N.; Boucher, E.; De Fromont, M.; Fondimare, A.; Molinié, V.; Piron, D.; Sibony, M.; Staroz, F.; Triller, M.; Peltier, E.; Thiounn, N.; Rubin, M.A.: Evaluation of the interobserver reproducibility of Gleason grading of prostatic adenocarcinoma using tissue microarrays, 2003, Human Pathology, 34(5), 444-449.
  27. Deliveliotis, C.; Skolarikos, A.; Karayannis, A.; Tzelepis, V.; Trakas, N.; Alargof, E.; Protogerou, V.: The prognostic value of p53 and DNA ploidy following radical prostatectomy, 2003, World Journal of Urology, 21, 171-176.
  28. Deutsche Gesellschaft für Urologie: Interdisziplinäre Leitlinie der Qualität S3 zur Früherkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms, 2009, Version 1.0.
  29. Di Silverio, F.; D`Eramo, G.; Buscarini, M.; Sciarra, A.; Casale, P.; Di Nicola, S.; Loreto, A.; Seccareccia, F.; De Vita, R.: DNA ploidy, Gleason score, pathological stage and serum PSA levels as predictors of disease-free survival in C-D1 prostatic cancer patients submitted to radical retropubic prostatectomy, 1996, European Urology, 30, 316-321.
  30. Di Silverio, F.; D`Eramo, G.; Caponera, M.; Persechino, F.; Eleuteri, P.; Cavallo, D.; De Vita, R.; Forte, D.: The prognostic value of DNA content in patients with prostatic carcinoma, 1992, European Urology, 21, 92-95.
  31. Dong, F., Kattan, M.W., Steyerberg, E.W., Jones, J.S., Stephenson, A.J., Schröder, F.H., Klein, E.A.: Validation of pretreatment nomograms for predicting indolent prostate cancer, 2008, Journal of Urology, 180 (1), 150-154.
  32. Elgamal, A. A., Van Poppel, H. P., Van der Voorde, W.M., Van Dorpe, J. A., Oyen, R. H., Baert, L. V.: Impalpable invisible stage T1c prostate cancer: characteristics and clinical relevance in 100 radical prostatectomy specimens – a different view. Journal of Urology, 1997, 157 (1), 244-250.
  33. Egevad, L.: Reproducibility of Gleason grading of prostate cancer can be improved by the use of reference images, 2001, Urology, 57, 291-295.
  34. Engelhard, M.: PSA-Kinetiken als Indikationsstellung zur Prostatastanzbiopsie, Med. Diss. Universität Düsseldorf, in Vorbereitung, 2011.
  35. Engers, R.: Reproducibility and reliability of tumor grading in urological neoplasms, 2007, World Journal of Urology, 25, 595-605.
  36. Eposti, P.L.: Cytologic malignancy grading of prostatic carcinoma by transrectal aspiration biopsy, 1971, Scandinavian Journal of Urology and Nephrology, 5, 199-205.
  37. Epstein., J.I., Walsh, P.C., Carmichael, M., Brendler, C.B.: Pathologic and clinical findings to predict tumor extent of nonpalpable (stage 1c) prostate cancer, 1994, Journal of the American Medical Association, 271 (5), 368-374.
  38. Epstein, J.I., Chan, D.W., Sokoll, LJ., Walsh, P.C., Cox, J., L., Rittenhouse, H., Wolfert, R., Carter, H.B.: Nonpalpable stage T1c prostate cancer: prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings, 1998, Journal of Urology, 160 (6), 2407-2411.
  39. Epstein, J.I., Walsh, P.C., Akingba, G., Carter, H.B.: The significance of prior benign needle biopsies in men subsequentially diagnosed with prostate cancer, 1999, Journal of Urology, 162 (5), 1649-1652.
  40. Epstein, J.I.; Amin, M.; Boccon-Gibod, L.; Egevad, L.; Humphrey, P.A.; Mikuz, G.; Newling, D.; Nilsson, S.; Sakr, W.; Srigley, J.R.; Wheeler, T.M.; Montironi, R. : Prognostic factors and reporting of prostate carcinoma in radical prostatectomy and pelvic lymphadenectomy specimens, 2005, Scandinavian Journal of Urology and Nephrology Supplement, 216, 34-63.
  41. Eskelinen, M.; Lipponen, P.; Majapuro, R.; Syrjänen, K.; Nordling, S.: DNA loidy, S phase fraction and G2 fraction as prognostic determinants in prostatic adenocarcinoma, 1991, European Urology, 20, 62-66.
  42. Esposti, P.L.: Cytologic malignancy grading of prostatic carcinoma by transrectal aspiration biopsy, 1971, Scandinavian Journal of Urology and Nephrology, 5, 199-205.
  43. Fordham, M.V.P.; Burdget, A.H.; Matthews, J.; Williams, G.; Cooke, T.: Prostatic carcinoma cell DNA content measured by flow cytometry and its relation to clinical outcome, 1986, British Journal of Surgery, 73, 400-403.
  44. Forsslund, G., Esposti, P. L., Nilsson, B., Zetterberg, A.: The prognostic significance of nuclear DNA-content in prostatic adenocarcinoma. 1992, Cancer, 69 (6), 1432 – 1439.
  45. Forsslund, G.; Nilsson, B.; Zetterberg, A.: Near tetraploid prostate carcinoma - Methodologic and prognostic aspects, 1996, Cancer, 78(8), 1748-1755.
  46. Frankfurt, O.S.; Chin, J.L.; Englander, L.S.; Greco, W.R.; Edson Pontes, J.; Rustum, Y.M.: Relationship between DNA Ploidy, glandular differentiation, and tumor spread in human prostate cancer, 1985, Cancer Research, 45, 1418-1423.
  47. Ghavamian, R., Blute, M.L., Bergstrahl, E.J., Slezak, J., Zincke, H.: Comparison of clinically nonpalpable prostate specific antigen detected (cT1c) versus palpable (cT2) prostate cancers in patients unsergoing radical retropubic prostatectomy, 1999, Urology 54 (1), 105-110.
  48. Giroud, F.; Haroske, G.; Reith, A.; Böcking, A.: Part II: Specific recommendations for quality assurance, 1998, Analytical Cellular Pathology, 17, 201-208.
  49. Glaessgen, A.; Hamberg, H.; Pihl, C.G.; Sundelin, B.; Nilsson, B.; Egevad, L.: Interobserver reproducibility of modified Gleason score in radical prostatectomy specimens, 2004, Virchows Archiv, 445(1), 17-21.
  50. Glaessgen, A.; Hamberg, H.; Pihl, C.G.; Sundelin, B.; Nilsson, B.; Egevad, L.: Interobserver reproducibility of percent Gleason grade 4/5 in prostate biopsies, 2004, Journal of Urology, 171, 664-667.
  51. Gleason, D.F.; Mellinger, G.T.; The Veterans Administration Cooperative Urological Research Group: Prediction of prognosis for prostatic for prostatic adenocarcinoma by combined histological grading and clinical staging, 1974, Journal of Urology, 111, 58-64.
  52. Goto, Y., Ohori, M., Arakawa, A., Kattan, M.W., Wheeler, T.M., Scardino, P.T.: Distinguishing clinically imortant from unimportant prostate cancers before treatment: value of systematic biopsies. Journal of Urology, 1996, 156 (3), 1059-1063.
  53. Greene, D. R.; Rogers, E.; Wessels, E.C.; Wheeler, T. M.; Taylor, S.R.; Santucci, R.A..; Thompson, T. C.; Scardino, P. T.: Some small prostate cancers are nondiploid by nuclear image analysis: Correlation of deoxyribonucleic acid Ppoidy Ssatus and pathological features, 1994, Journal of Urology, 151, 1301-1307.
  54. Griffiths, D.F.R; Melia, J.; McWilliam, L.J.; Ball, R.Y.; Grigor, K.; Harnden, P.; Jarmulowicz, M.; Montironi, R.; Moseley, R.; Waller, M.; Moss, S.; Parkinson, M.C.: A study of Gleason score interpretation in different groups of UK pathologists, techniques for improving reproducibility, 2006, Histopathology, 48, 655-662.
  55. Häggman, M.; de la Torre, M.; Brändstedt, S.; Norlén, B.J.; Norberg, M.; Busch, C.: Pre- and postoperative DNA ploidy patterns correlated to pT-stage, histological grade and tumour volume in total prostatectomy specimens, 1994, Scandinavian Journal of Urology and Nephrology Supplement, 28, 59-66.
  56. Haroske, G.; Baak, J.P.A.; Danielsen, H.; Giroud, F.; Gschwendtner, A.; Oberholzer, M.; Reith, A.; Spieler, P.; Böcking, A.: Fourth updated ESACP consensus report on diagnostic DNA image cytometry, 2001, Analytical Cellular Pathology, 23, 89-95.
  57. Haroske, G.; Giroud, F.; Reith, A.; Böcking, A.: Part I: Basic considerations and recommendations for preparation, measurement and interpretation, 1998, Analytical Cellular Pathology, 17, 189-200.
  58. Haroske, G.; Meyer, W.; Oberholzer, M.; Böcking, A.; Kunze, K.D.: Competence on demand in DNA image cytometry, 2000, Pathology Research and Practice, 196, 285-291.
  59. Hawkins, C.A.; Bergstralh, E.J.; Lieber, M.M.; Zincke, H.: Influence of DNA ploidy and adjuvant treatment on progression and survival in patients with pathologic stage T3 (PT3) prostate cancer after radical retropubic prostatectomy, 1995, Journal of Urology, 46, 356-364.
  60. Helpap, B.; Egevad, L.: Clinical insignificance of prostate cancer: are there morphological findings?, 2009, Urologe A, 48(2), 170-174.
  61. Helap, B, Hartmann, A. , Wernert, N.: Anleitung zur pathologisch-anatomischen Diagnostik von Prostatatumoren des Bundesverbandes Deutscher Pathologen e.V. und der Deutschen Gesellschaft für Pathologie e.V., Version 2.0, März 2011. www.prostata-shg.de.
  62. Hirano, D., Werahera, P.N., Crawford, E.D., Lucia, M.S., DeAntoni, E.P., Miller, G.J.: Morphological analysis and classification of latent prostate cancer using a 3-dimensional computer algorithm: analysis of tumor volume, grade, tumor doubling time and lifetime expectancy, 1998, Journal of Urology, 159 (4), 1265-1269.
  63. Horninger, W., Rogatsch, H., Reissigl., A., Volgger, H., Klocker, H., Hobisch, A., Bartsch, G.: Correlation between preoperative predictors and pathologic features in radical prostatectomy specimens in PSA-based screening, 1999, Prostate, 40 (1), 56-61.
  64. Hussain, M. H.; Powell, I.; Zaki, N.; Maciorowski, Z.; Sakr, W.; KuKuraga, M.; Visscher, D.; Haas, G.P.; Pontes, J.E.; Ensley, J. F.: Flow cytometric DNA analysis of fresh prostatic resections - Correlation with conventional prognostic parameters in patients with prostate cancer, 1993, Cancer, 72(10), 3012-3019.
  65. Iczkowski, K.A.; Bostwick, D.G.: The pathologist as optimist: cancer grade deflation in prostatic needle biopsies, 1998, American Journal of Surgical Pathology, 22, 1169-1170.
  66. Irwin, M.B., Trapasso, J.G.: Identification of insignificant prostate cancers: analysis of preoperative parameters. Urology, 1994, 44 (6), 862-867.
  67. Isharwal, S.; Miller, M.C.; Epstein, J.I.; Mangold, L.A.; Humphreys, E.; Partin A.W.; Veltri, R.W.: DNA ploidy as surrogate for biopsy Gleason score for preoperative organ versus nonorgan-confined prostate cancer prediction, 2009, Urology, 73(5), 1092-1097.
  68. Jack, G.S., Cookson, T.A., Coffey, C.S., Vader, V., Roberts, R.L., Chang, S.S., Smith, J.A., Jr., Shappell, S.B.: Pathoogical parameters of radical prostatectomy for clinical stages T1c versus T2 prostate adenocarcinoma: decreased pathological stage and increased detection of transition zone tumors, 2002, Journal of Urology, 168 (2), 519-524.
  69. Kassenärztliche Bundesvereinigung. Einheitlicher Bewertungsmaßstab (EBM). Band 1. 01.01.2008, Deutscher Ärzte-Verlag, Köln, Seite 305.
  70. Kattan, M.W., Eastham, J.A., Wheeler, T.M., Maru, N., Scardino, P.T., Erbersdobler, A., Graefen, M., Huland, H., Koh, H., Shariat, S.H., Slawin, K.M., Ohori, M.: Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors, 2003, Journal of Urology, 170 (5), 1792-1797.
  71. Khoo, V.S.; Pollack, A.; Cowen, D.; Joon, D.L.; Patel, N.; Terry N.H.A.; Zagars, G.K.; von Eschenbach, A.C.; Meistrich, M.L.; Troncoso, P.: Relationship of Ki-67 labeling index to DNA-ploidy, S-phase fraction, and outcome in prostate cancer Treated with radiotherapy, 1999, Prostate, 41, 166-172.
  72. Kristiansen, G.: Was bedeutet der neue Gleason-Score für den Kliniker, 2009
  73. Lee., A.K., Doytchinova, T., Chen., M.H., Renshaw, A.A., Weinstein, M., Richie, J.P., D`Amico, A.V.: Can the core length involved with prostate cancer identify clinically insignificant disease in low risk patients diagnosed on the basis of a single positive core? 2003, Urologic Oncology, 21 (2), 123-127.
  74. Lessells, A.M.; Burnett, R.A.; Howatson, S.R. et al.: Observer variability in the histopathological reporting of needle biopsy specimens of the prostate, 1997, Human Pathology, 28, 646-649.
  75. Leung, C.S., Zbieranowski, I., Demers, J., Murray, D.: DNA image cytometry of prostatic Carcinoma: A comparison of needle core biopsy and subsequent prostatectomy specimens. 2004, Modern Pathology, / (2), 195-199
  76. Loeb, S., Roehl, K.A., Thaxton, C.S., Catalona, W.J.: Combined prostate-specific antigen density and biopsy features to predict “clinically insignificant” prostate cancer, 2008, Urology, 72 (1), 143-147.
  77. Martínez Jabaloyas, J. M.; Jiménez-Sánchez, A.; Ruiz Cerdá, J. L.; Sanz Chinesta, S.; Sempere, A.; Jiménez Cruz, J. F.: Valor pronóstico de la ploidía del ADN y la morfometría nuclear en el cáncer de próstata metastásico, 2004, Actas Urológicas Españolas, 28(4), 298-307.
  78. Martínez-Jabaloyas, J. M.; Ruiz-Cerdá, J. L.; Hernández, M.; Jiménez, A.; Jiménez-Cruz, F.: Prognostic value of DNA ploidy and nuclear morphometry in prostate cancer treated with androgen deprivation, 2002, Urology, 59, 715-720.
  79. Miyake, H., Sakai, I., Harada, K., Hara, I., Eto, H.: Prediction of potentially insignificant prostate cancer in men undergoing radical prostatectomy for clinically organ-confined disease, 2005, International Journal of Urology, 12 (3), 270.274.
  80. Mikami, Y.; Manabe, T.; Epstein, J.I. et al: Accuracy of Gleason grading by practicing pathologists and impact of education on improving agreement, 2003, Human Pathology, 34, 658-665.
  81. Milcent, S.; Lorenzato, M.; Enaschescu, D.; Enaschescu, C.; Birembaut, P.; Staerman, F.: La ploïdie cellulaire: facteur prédictif de cancer de prostate localement avancé, 2007, Progrès en Urologie, 17, 819-823.
  82. Miller, J.; Horsfall, D.J.; Marshall, V.R.; Rao, D.M.; Leong, A.S.-Y.: The prognostic value of deoxyribonucleic acid flow cytometric analysis In stage D2 prostatic carcinoma, 1991, Journal of Urology, 145, 1192-1196.
  83. Montgomery, B.T.; Nativ, O.; Blute, M.L.; Farrow, G.M.; Myers, R.P., Zincke, H.; Therneau, T.M.; Lieber, M.M.: Stage B prostate adenocarcinoma. A flow cytometric nuclear DNA ploidy analysis, 1990, Archives of Surgery, 125, 327-331.
  84. Mora, L.B.; Moscinski, L.C.; Diaz, J.I.; Blair, P.; Cantor, A.B.; Pow-Sang, J.M.: Stage B Prostate cancer: correlation of DNA ploidy analysis with hstological and clinical parameters, 1999, Cancer Control, 6(6), 587-591.
  85. Moussa, M.; Song, T.Y.; Frei, J.V.; Peers, G.; Chin, J.L.: DNA cytometric proliferative index predicting organ confinement in clinical stage-B prostate cancer, 1997, Clinical and Investigative Medicine, 20(2), 119-126.
  86. Nativ, O.; Winkler, H.Z.; Raz, Y.; Therneau, T.M.; Farrow, G.M.; Myers, R.P.; Zincke, H.; Lieber, M.M.: Stage C prostatic adenocarcinoma: Flow cytometric nuclear DNA ploidy analysis, 1989, Mayo Clinic Proceedings, 64, 911-919.
  87. Ochiari, A., Troncoso, P., Chen, M. E., Lloreta, J., Babian, R. J.: The relationship between tumor volume and the number of positive cores in men undergoing mutisite extended biopsy: implication for expectant management. Journal of Urology, 2005, 174 (6), 2164 – 2168.
  88. Özdamar, S.O.; Sarikaya, S.; Yildiz, L.; Atilla, M.K.; Kandemir, B.; Yildiz, S.: Intraobserver and interobserver reproducibility of WHO and Gleason histologic grading systems in prostatic adenocarcinomas, 1996, International Urology and Nephrology, 28(1), 73-77.
  89. Oxford Centre for Evidence based Medicine, 2009, http://www.cebm.net/index.aspx?o, 21.04.2011.
  90. Peters-Gee, J. M.; Miles, B.J.; Cerny, J.C.; Gaba, A.R.; Jacosbsen, G.; Crissman, J.D.: Prognostic significance of DNA quantitation in stage D1 prostate carcinoma with the use of image analysis, 1992, Cancer, 70(5), 1159-1165.
  91. Pollack, A.; Grignon, D. J.; Heydon, K. H.; Hammond, E.H.; Lawton, C. A.; Mesic, J. B.; Fu, K. K.; Porter, A. T.; Abrams, R. A.; Shipley, W. U.: Prostate cancer DNA ploidy and response to salvage hormone therapy after radiotherapy with or without short-term total androgen blockade: An analysis of RTOG 8610, 2003, Journal of Clinical Oncology, 21(7), 1238-1248.
  92. Pollack, A.; Troncoso, P.; Zagars, G.K.; von Eschenbach, A.C.; Mak, A.C.; Wu, C.S.; Terry, N.H.: The significance of DNA-ploidy and S-phase fraction in node-positive (stage D1) prostate cancer treated with androgen ablation, 1997, Prostate, 31, 21-28.
  93. Pollack, A.; Zagars, G.K.; El-Naggar, A.K.; Gauwitz, M.D.; Terry, N.H.A.: Near-Diploidy: A new prognostic factor for clinically localized prostate cancer treated with external beam radiation therapy, 1994, Cancer, 73(7), 1895-1903.
  94. Pretorius, M.E.; Waehre, H.; Abeler, V.M.; Davidson, B.; Vlatkovic, L.; Lothe, R.A.; Giercksky, K.-E.; Danielsen, H.E.: Large scale genomic instability as an additive prognostic marker in early prostate cancer, 2009, Cellular Oncology, 31, 251-259.
  95. Roel, K.A., Antenor, J.A., Catalona, W.J.: 2002, Journal of Urology, 167 (2), 2435-2439.
  96. Recker, F., Kwiatkowski, M.K., Huber, A., Stamm, B., Lehmann, K., Tscholl, R.: Prospective detection of clinically relevant prostate cancer in the prostate specific antigen range 1 to 3 ng/ml combined with free-to-total ratio 20% or less: the Aarau experience, 2001, Journal of Urology, 166 (3), 851-855.
  97. Ross, J.S.; Figge, H.; Bui, H. X.; del Rosario, A. D.; Fisher, H.A.G; Nazeer, T.; Jennings, T.A.; Ingle, R.; Kim, D.N.: E-Cadherin Expression in Prostatic Carcinoma Biopsies: Correlation with Tumor Grade, DNA Content, Pathologic Stage, and Clinical Outcome, 1994, Modern Pathology, Vol. 7, No. 8, 835-841
  98. Ross, J.S.; Figge, H.; Bui, H. X.; del Rosario, A. D.; Jennings, T. A.; Rifkin, M.D.; Fisher, H.A.G.: Prediction of pathologic stage and postprostatectomy disease recurrence by DNA ploidy analysis of initial needle biopsy specimens of prostate cancer, 1994, Cancer, 74(10), 2811-2818.
  99. Ross, J.S.; Jennings, T.A.; Nazeer, T.; Sheehan, C.E.; Fisher, H.A.G; Kauffman, R.A.; Anwar, S.; Kallakury, B.V.S.: Prognostic factors in prostate cancer, 2003, American Journal of Clinical Pathology, 120 (Suppl 1), 85-100.
  100. Ross, J.S.; Sheehan, C.E.; Ambros, R.A.; Nazeer, T.; Jennings, T.A.; Kaufman Jr., R.P.; Fisher, H.A.; Rifkin, M.D.; Kallakury, B.V.: Needle biopsy DNA ploidy status predicts grade shifting in prostate cancer, 1999, American Journal of Surgical Pathology, 23(3), 296-301.
  101. Rousselet, M.C.; Saint-Andre, J.P.; Six, P.; Soret, J.Y.: Reproducibility and prognostic value of Gleason`s and Gaeta`s histological grades in prostatic carcinoma, 1986, Annales d` Urologie, 20(5), 317-322.
  102. Sakr, W.A.; Grignon, D.J.: Prostate Cancer: Indicators of Aggressiveness, 1997, European Urology, 32(Suppl 3), 15-23.
  103. Schröder, F.; Tribukait, B.; Böcking, A.; de Vere White, R.; Koss, L.; Lieber, M.; Stenkvist, B.; Zetterberg, A.: Clinical utility of cellular DNA measurements in prostate carcinoma, 1994, Scandinavian Journal of Urology and Nephrology Supplement, 162, 51-64.
  104. Sokoloff, M. H., Yang, X. J., Fumo, M., Mhoon, D., Brendler, C. B.: Ccharacterizing prostatic adenocarcinoma in men with a serum prostate specific antigen level of < 4.0 ng/ml. British Journal of Urology International, 2004, 93 (4), 499-502.
  105. Song, J.; Cheng, W.S.; Cupps, R.E.; Earle, J.D.; Farrow, G.M.; Lieber, M.M.: Nuclear deoxyribonucleic acid content measured by static cytometry: Important prognostic association for patients with clinically localized prostate carcinoma treated by external beam radiotherapy, 1992, Journal of Urology, 147, 794-797.
  106. Spitz, M.R., Strom, S.S., Yamamura, Y., Troncoso, P., Babaian, R.J., Scardino, P.T., Wheeler, T., Amos, C.I., von Eschenbach, A., Kagan, J.: Epidemiologic determinants of clinically relevant prostate cancer, 2000, International Journal of Clinical Practise, 89 (3), 259-264.
  107. Stamey, T.A., Freiha, F.S., McNeal, J.E., Redwine, E.A., Whittemore, A.S., Schmid, H.P.: Localized prostate cancer. Relationship of tumor volume to clinical significance for the treatment of prostate cancer, 1993, Cancer, 71 (3 Suppl.), 933-938.
  108. Stephenson, R.A.; James, B.C.; Gay, H.; Fair, W.R.; Whitmore Jr., W.F.; Melamed, M.R.: Flow cytometry of prostate cancer: Relationship of DNA content to survival, 1987, Cancer Research, 47, 2504-2507.
  109. Steyerberg, E.W., Roobol., M.J., Kattan, M.W., van der Kwast, T., de Koning, H.J., Schröder, F.H.: Prediction of indolent prostate cancer: validation and updating of a prognostic nomogram, 2007, Journal of Urology, 177 (1), 107-112.
  110. Svanholm, H.; Mygind, H.: Prostatic carcinoma reproducibility of histologic grading, 1985, Acta Pathologica Microbiologica Scandinavica Section A, 93, 67-71.
  111. Tavares, A. S., Costa, J., De Carvalho, A., Reis, M.: Tumour ploidy and prognosis in carcinomas of the bladder. British Journal of Cancer, 1966, 20, 438 – 441.
  112. Terris, M.K., Haney, D.J., Johnstone, I.M., McNeal, J.E., Stamey, T.A.: Prediction of prostate cancer volume using prostate-specific antigen levels, transrectal ultrasound, and systematic sextant biopsies, 1995, Urology, 45 (1), 75-80.
  113. Tils, M.: DNA-Malignitäts-Gradierung Beim Prostatakarzinom – Reproduzierbarkeit, Korrelation mit dem Gleason-Score und dem Staging . Med. Diss., Universität Düsseldorf, in Vorbereitung, 2011.
  114. Tribukait, B.: Nuclear deoxyribonucleic acid determination in patients with prostate carcinomas: Clinical research and application, 1993, European Urology, 23(2), 64-76.
  115. Tucci Jr., S.; Blumenfeld, W.; Narayan, P.: Ploidy status correlates with outcome in stage B prostate adenocarcinoma, 1994, Brazilian Journal of Medical and Biological Research, 27, 25-32.
  116. Uemura, H., Hushino, K., Sasaki, T., Mioshi, Y., Ishiguro, H., Inayama, Y, Kubeto, Y.: Usefulness of the 2005 International Society of Urological Pathology Gleason grading system in prostate biopsy and radical prostatectomy. British Journal of Urology, September 2008
  117. UICC International Union Against Cancer, Hrsg.: Wittekind, Ch.; Meyer, H.-J., Bootz, F.: TNM Klassifikation maligner Tumoren, Springer 2002, 6.Auflage.
  118. Veltri, R.W.; Partin, A.W.; Epstein, J.E.; Marley, G.M.; Miller, C.M.; Singer, D.S.; Patton, K.P.; Criley, S.R.; Coffey, D.S.: Quantitative nuclear morphometry, Markovian texture descriptors, and DNA content captured on a CAS-200 image analysis system, combined Wwth PCNA and Her-2/neu immunohistochemistry for prediction of prostate cancer progression, 1994, Journal of Cellular Biochemistry, 19, 249-258.
  119. Vesalainen, S.; Nordling, S.; Lipponen, P.; Talja, M.; Syrjänen, K.: Progression and survival in prostatic adenocarcinoma: a comparison of clinical stage, Gleason grade, S-phase fraction and DNA ploidy, 1994, British Journal of Cancer, 70, 309-314.
  120. Visakorpi, T.; Kallioniemi, O.-P.; Paronen, I.Y.I.; Isola, J.J.; Heikkinen, A.I.; Koivula, T.A.: Flow cytometric analysis of DNA ploidy and S-phase fraction from prostatic carcinomas: implications for prognosis and response to endocrine therapy, 1991, British Journal of Cancer, 64, 578-582.
  121. Voges, G. E.; Eigner, E. B.; Ross, W.; Sussman, H.; Stöckle, M.; Freiha, F.S.; Stamey, T. A.: Pathologic parameters and flow cytometric Ppoidy analysis in predicting recurrence in carcinoma of the prostate, 1993, European Urology, 24, 132-139.
  122. Wang, N., Wilkin, C., Böcking, A., Tribukait, B.: Evaluation of tumor heterogeneity of prostate carcinoma by flow- and image DNA-cytometry. 2000, Analytical Cellular Pathology, 20, 49 – 62.
  123. Winkler, H.Z.; Rainwater, L.M.; Myers, R.P.; Farrow, G.M.; Therneau, T.M.; Zincke, H.; Lieber, M.M.: Stage D1 prostatic adenocarcinoma: Significance of nuclear DNA ploidy patterns studied by flow cytometry, 1988, Mayo Clinic Proceedings, 63, 103-112.